[Tumor markers in gynecologic diseases].

Area of Science:

• Oncology
• Biochemistry

Context:

• Gynecologic oncology involves complex diagnostics.
• Accurate tumor marker assessment is crucial for patient management.

Purpose:

• To evaluate the diagnostic and prognostic utility of serum tumor markers CA 125, CEA, and CA 153.
• To assess the correlation of these markers with various gynecologic malignancies and benign conditions.

Summary:

• CA 125 demonstrated high sensitivity (90%) in ovarian carcinomas, often exceeding 500 U/ml in primary tumors.
• Elevated CA 125 was also observed in non-epithelial ovarian cancers, metastases, and even benign gynecologic conditions.
• CA 153 showed lower prevalence in early breast cancer (40%) but higher rates in recurrences (72%).
• Combined analysis of CA 153 and CEA provided further insights into tumor status.

Impact:

• These findings underscore the significance of CA 125 and CA 153 as biomarkers in gynecologic oncology.
• The study highlights the importance of these markers, particularly in the post-treatment surveillance of cancer patients.
• Results suggest potential for improved monitoring and management strategies in ovarian and breast cancer care.